Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.

IPO Year: 2017

Exchange: NASDAQ

Website: ovidrx.com